Riskpilot← Back to searchSign inGet full accessNordic Preclinical Sciences AB
ABActiveOrg 5593013724Heimdalsgatan 12 Lgh-1101Research and experimental development on natural sciences and engineering · NACE 7210Est. 20210 employees
Revenue 2024
SEK 124K
EBITDA margin
1.6%
Equity ratio
89.3%
Financial strength
Net profit 2024
SEK 2K
0 employees
| Revenue | SEK 124K | — |
| EBITDA | SEK 2K | — |
| Net profit | SEK 2K | — |
| Total assets | SEK 28K | +12% |
| Equity | SEK 25K | +0% |
| Employees | 0 | — |
Legal name
Nordic Preclinical Sciences AB
Org number
5593013724
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
11 februari 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för Aktiebolagets verksamhet är att bedriva biologiska och kemiska screening- eller testtjänster till våra kunder av olika kemikalier, biomolekyler, biomaterial, inklusive läkemedelskandidater.
Address
Heimdalsgatan 12 Lgh-1101
Email
souravpm@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 124 |
| Staff expenses | — | −0 | — | — | — |
| EBITDA | — | 0 | — | — | 2 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | 0 | 0 | 0 | 0 | 2 |
| Net financials | — | 0 | — | — | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 3 |
| Tax | −0 | −0 | −0 | −0 | −1 |
| Net profit | 0 | 0 | 0 | 0 | 2 |
| Item | 2021 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 25 | 0 | 25 | 25 | 28 |
| Equity | 25 | 0 | 25 | 25 | 25 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 0 | 3 |
| Total debt | — | 0 | — | — | 3 |
EBITDA margin
1.6%
This company
15.8%
Market median
-90% vs market
20212024
Equity ratio
89.3%
This company
38.2%
Market median
+134% vs market
20212024
Return on equity
8.0%
This company
18.4%
Market median
-57% vs market
20212024
Net profit margin
1.6%
This company
8.1%
Market median
-80% vs market
20212024
Asset turnover
4.43×
This company
1.12×
Market median
+296% vs market
20212024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-02-11 – 2021-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-02-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SP Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Board of Directors | 2026 | |
| Former (1) | ||
| Board of Directors | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nordic Preclinical Sciences AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sourav Prasanna Mukherjee | Chief Executive Officer | 0 companies |
| Ákos Végvári | Board of Directors | 0 companies |
| Bengt Sherif Fadeel | Chairman | 0 companies |
| Sanchali Gupta Mukherjee | Board of Directors | 0 companies |